Teleflex (NYSE:TFX) Shares Gap Up – Should You Buy?

Teleflex Incorporated (NYSE:TFX) gapped up before the market opened on Wednesday . The stock had previously closed at $124.75, but opened at $136.00. Teleflex shares last traded at $136.7230, with a volume of 619,995 shares.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Private-equity takeover speculation (CVC Capital Partners + GTCR) has increased the odds of a strategic outcome or buyout premium, which pushed the shares higher in pre-market trade earlier this week. Teleflex gains on report PE firms teamed up for takeover offer (update) Teleflex jumps on fresh take-private bid chatter involving CVC and GTCR Teleflex Stock Surges Over 8% In Pre-Market Trading: Here’s Why
• Neutral Sentiment: Teleflex received a relative strength rating upgrade and hit a technical threshold, which can attract momentum traders but doesn’t change fundamentals. Teleflex scores relative strength rating upgrade; hits key threshold
• Neutral Sentiment: Teleflex scheduled its Q1 2026 earnings conference call for May 7 — a near-term event that could clarify progress on restructuring, cost saves and the planned portfolio separation. Investors may trade around any operational details or guidance updates. Teleflex Announces First Quarter 2026 Earnings Conference Call Information
• Negative Sentiment: Fundamentals remain a concern after Teleflex’s latest-quarter results showed a significant revenue decline and an EPS miss; management’s FY2026 EPS guide (6.25–6.55) sits below some analyst expectations and prior-year earnings, keeping downside risk if recovery is slower than hoped. The Q4 2024 earnings transcript provides details investors are still parsing. Teleflex (TFX) Q4 2024 Earnings Transcript

Analyst Ratings Changes

A number of equities analysts have recently weighed in on TFX shares. Raymond James Financial upgraded Teleflex from a “market perform” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Friday, March 27th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Teleflex in a research note on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Needham & Company LLC raised their price objective on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $138.50.

Teleflex Stock Performance

The stock has a 50 day simple moving average of $116.20 and a 200 day simple moving average of $116.53. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The stock has a market cap of $6.05 billion, a P/E ratio of -6.65, a price-to-earnings-growth ratio of 1.00 and a beta of 0.84.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 EPS for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. During the same quarter last year, the business earned $3.89 EPS. Teleflex’s revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities analysts expect that Teleflex Incorporated will post 6.77 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were paid a $0.34 dividend. The ex-dividend date was Friday, March 6th. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is presently -6.62%.

Hedge Funds Weigh In On Teleflex

Hedge funds and other institutional investors have recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB increased its stake in shares of Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. Banque Cantonale Vaudoise increased its stake in shares of Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares during the last quarter. Hantz Financial Services Inc. increased its stake in shares of Teleflex by 248.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Teleflex in the 3rd quarter valued at $35,000. Finally, V Square Quantitative Management LLC bought a new position in shares of Teleflex in the 4th quarter valued at $37,000. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.